One more step towards justifying targeted treatment for insomnia

Sleep

Volumn 34, Issue 4, 2011, Pages 417-418

  Perlis, Michael L ^a   Gehrman, Philip ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HUMAN; INSOMNIA; JOB PERFORMANCE; NOTE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR;

EID: 79953654792     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/34.4.417     Document Type: Note

References (8)

1. Smith MT, Perlis ML, Park A, Pennington JY, Orff HJ, Giles DE. Comparative meta-analysis of cognitive-behavioraltherapy and pharmacotherapy for insomnia. Sleep 2000;23 Supplemental #1:A321-A322.
2. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151:1172-80. (Pubitemid 24240960)
3. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF III, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7. (Pubitemid 28013492)
4. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049-57.
5. Fullerton P. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care 2006;S246-52.
6. Ozminkowski RJ, Wang SH, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-73. (Pubitemid 46494401)
7. Sarsour K, Kalsekar A, Swindle R, Foley K, Walsh JK. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep 2011;34:443-50.
8. Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep 2009;32:817-24.